Raymond James analyst Ryan Deschner raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $77 from $73 and keeps a Strong Buy rating on the shares. The price target increase is driven by bile acid portfolio and Livmarli net sales in addition to raised guidance for fiscal 2025, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Buy Rating on Mirum Pharmaceuticals: Promising Phase 2b VANTAGE Study Results and Strong Market Potential
- Mirum’s volixibat shows ‘best-in-class potential,’ says Citi
- Mirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP
- Mirum Pharmaceuticals Reports Robust Q1 2025 Growth
- Mirum Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating